

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT										
NATURE OF CONVEYANCE:	ASSIGNMENT										
CONVEYING PARTY DATA											
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>PURAPHARM INTERNATIONAL (H.K.) LIMITED</td> <td>12/03/2012</td> </tr> <tr> <td>VERSITECH LIMITED</td> <td>12/03/2012</td> </tr> </tbody> </table>		Name	Execution Date	PURAPHARM INTERNATIONAL (H.K.) LIMITED	12/03/2012	VERSITECH LIMITED	12/03/2012				
Name	Execution Date										
PURAPHARM INTERNATIONAL (H.K.) LIMITED	12/03/2012										
VERSITECH LIMITED	12/03/2012										
RECEIVING PARTY DATA											
<table border="1"> <tr> <td>Name:</td> <td>PURAPHARM COMPANY LIMITED</td> </tr> <tr> <td>Street Address:</td> <td>Suite 4002, Jardine House</td> </tr> <tr> <td>Internal Address:</td> <td>1 Connaught Place, Central</td> </tr> <tr> <td>City:</td> <td>Hong Kong</td> </tr> <tr> <td>State/Country:</td> <td>CHINA</td> </tr> </table>		Name:	PURAPHARM COMPANY LIMITED	Street Address:	Suite 4002, Jardine House	Internal Address:	1 Connaught Place, Central	City:	Hong Kong	State/Country:	CHINA
Name:	PURAPHARM COMPANY LIMITED										
Street Address:	Suite 4002, Jardine House										
Internal Address:	1 Connaught Place, Central										
City:	Hong Kong										
State/Country:	CHINA										
<table border="1"> <tr> <td>Name:</td> <td>VERSITECH LIMITED</td> </tr> <tr> <td>Street Address:</td> <td>Pokfulam Road</td> </tr> <tr> <td>Internal Address:</td> <td>Finance Office, University of Hong Kong</td> </tr> <tr> <td>City:</td> <td>Hong Kong</td> </tr> <tr> <td>State/Country:</td> <td>CHINA</td> </tr> </table>		Name:	VERSITECH LIMITED	Street Address:	Pokfulam Road	Internal Address:	Finance Office, University of Hong Kong	City:	Hong Kong	State/Country:	CHINA
Name:	VERSITECH LIMITED										
Street Address:	Pokfulam Road										
Internal Address:	Finance Office, University of Hong Kong										
City:	Hong Kong										
State/Country:	CHINA										
PROPERTY NUMBERS Total: 1											
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>12647843</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	12647843						
Property Type	Number										
Application Number:	12647843										
CORRESPONDENCE DATA											
Fax Number:	3523725800										
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>											
Phone:	(352) 375-8100										
Email:	drs@slepatents.com										
Correspondent Name:	David R. Saliwanchik										
Address Line 1:	P.O. Box 142950										
Address Line 4:	Gainesville, FLORIDA 32614-2950										
ATTORNEY DOCKET NUMBER:	PURA.100XC1										
PATENT											

NAME OF SUBMITTER:

David R. Saliwanchik

Total Attachments: 5

source=Executed-Assignment-2#page1.tif

source=Executed-Assignment-2#page2.tif

source=Executed-Assignment-2#page3.tif

source=Executed-Assignment-2#page4.tif

source=Executed-Assignment-2#page5.tif

ASSIGNMENT

WHEREAS, **PuraPharm International (H.K.) Limited**, having a place of business at Suite 4002, Jardine House, 1 Connaught Place, Central, Hong Kong, China and **Versitech Limited**, having a place of business at Pokfulam Road, Finance Office, University of Hong Kong, Hong Kong, China, have rights in and to the following intellectual property:

- 1) Invention entitled NOVEL COMPOUNDS AND USES THEREOF FOR TREATING INFLAMMATION AND MODULATING IMMUNE RESPONSES, for which an application for United States Letters Patent was filed January 12, 2009, Serial No. 61/143,925;
- 2) Invention entitled NOVEL COMPOUNDS AND USES THEREOF FOR TREATING INFLAMMATION AND MODULATING IMMUNE RESPONSES, for which an application for United States Letters Patent was filed December 28, 2009, Serial No. 12/647,843;

AND

- 3) Invention entitled COMPOUNDS AND USES THEREOF FOR TREATING INFLAMMATION AND MODULATING IMMUNE RESPONSES, for which an application for United States Letters Patent was filed on December 28, 2009, as Serial No. PCT/IB2009/055970.

WHEREAS, **PuraPharm Company Limited**, having a place of business at Suite 4002, Jardine House, 1 Connaught Place, Central, Hong Kong, China and **Versitech Limited**, having a place of business at Pokfulam Road, Finance Office, University of Hong Kong, Hong Kong, China are desirous of acquiring the entire right, title, and interest in and to said invention and in and to any Letters Patent which may be granted therefor in the United States and in any and all foreign countries;

NOW, THEREFORE, in view of valuable consideration, receipt of which is hereby acknowledged, **PuraPharm International (H.K.) Limited** and **Versitech Limited**, have sold, assigned, and transferred, and by these presents does sell, assign, and transfer, unto said **PuraPharm Company Limited** and **Versitech Limited**, their successors and assigns, the full and exclusive right to the said invention in the United States and its territorial possessions and in all foreign countries and the entire right, title, and interest in and to any and all Letters Patent which may be granted therefor in the United States and its territorial possessions and in any and all foreign countries and in and to any and all divisions, reissues, continuations, and extensions thereof.

Docket No. PURA.100P
Docket No. PURA.100XC1
Docket No. PURA. 100XC1PCT

PuraPharm International (H.K.) Limited and **Versitech Limited** hereby authorize and request the Patent Office Officials in the United States and in any and all foreign countries to issue any and all of said Letters Patent, when granted, to **PuraPharm Company Limited** and **Versitech Limited**, as the assignees of the entire right, title, and interest in and to the same, for the sole use and behoof of **PuraPharm Company Limited** and **Versitech Limited**, their successors and assigns.

FURTHER, **PuraPharm International (H.K.) Limited** and **Versitech Limited** agree that they will communicate to said **PuraPharm Company Limited** and **Versitech Limited**, or their representatives, any facts known to it respecting said invention; testify in any legal proceedings; sign all lawful papers; execute all divisional, continuation, substitution, renewal, and reissue applications; execute all necessary assignment papers to cause any and all of said Letters Patent to be issued to said **PuraPharm Company Limited** and **Versitech Limited**; make all rightful oaths; and generally do everything possible to aid the said **PuraPharm Company Limited** and **Versitech Limited**, their successors and assigns, to obtain and enforce proper protection for said invention in the United States and in any and all foreign countries.

IN TESTIMONY WHEREOF, I, the undersigned authorized representative of **PuraPharm International (H.K.) Limited**, have hereunto set my hand this 3rd day of December, 2012.

Signed 

Name Abraham Chan

Title President

PuraPharm International (H.K.) Limited
Suite 4002, Jardine House
1 Connaught Place, Central
Hong Kong, China


STATEMENT BY WITNESS

I, Vivienne Lee, whose full post office
(Name of witness)
address is Units 201 - 207, 2/F, Wireless Centre,
Hong Kong Science Park, Tai Po, NT.
(Address of witness)

hereby declare that I was personally present and did see the above-named person, personally known to me to be the person named in the assignment, duly sign and execute the same.

03 December 2012

Date


Signature

IN TESTIMONY WHEREOF, I, the undersigned authorized representative of **Versitech Limited**, have hereunto set my hand this 3rd day of December, 2012.

Signed 

Name Mr. Harrison Yu Tze Shan

Title Deputy Managing Director

Versitech Limited
Pokfulam Road, Finance Office
University of Hong Kong
Hong Kong, China

STATEMENT BY WITNESS

I, Alison Siu, whose full post office
(Name of witness)
address is Room 405A, Cyberport A, 100 Cyberport Road, Hong Kong
(Address of witness)

hereby declare that I was personally present and did see the above-named person, personally known to me to be the person named in the assignment, duly sign and execute the same.

03 December 2012
Date


Signature

